PMID- 26998057
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 11
IP  - 3
DP  - 2016 Mar
TI  - Assessment of ALK gene fusions in lung cancer using the differential expression 
      and exon integrity methods.
PG  - 1651-1656
AB  - Anaplastic lymphoma kinase (ALK) gene fusion is a driving mutation underlying the 
      development of non-small cell lung cancer (NSCLC). Accurate detection of ALK 
      fusion is critical for the use of ALK inhibitors in the treatment of NSCLC. 
      Commonly utilized methods for ALK detection include fluorescence in situ 
      hybridization (FISH) and immunohistochemistry (IHC). However, these methods are 
      time-consuming and costly. In the present study, a method for assessing ALK gene 
      fusion based on the differential expression levels of the ALK kinase and 
      non-kinase domains was developed and evaluated, with the aim of providing a 
      convenient and reliable method for the detection of ALK fusion. In addition, 
      another method was established to determine the integrity of exons 19-20 and 
      20-21 of ALK, two genomic loci that are typically broken in ALK fusions. These 
      novel methods were applied to detect ALK fusion in 100 NSCLC patients, and were 
      compared with IHC and FISH methods. The novel methods developed in the present 
      study successfully detected ALK fusions in 10 samples. The concordances between 
      the novel methods and IHC and FISH were 100%. Furthermore, the differential 
      expression method was able to detect ALK fusions in cell-free urine samples, 
      which was advantageous over FISH and IHC. The novel methods developed in the 
      present study are cost-effective and easy to perform, and may provide simple and 
      convenient techniques for the clinical assessment of ALK fusions, facilitating 
      the use of targeted therapy for NSCLC.
FAU - Huang, Qing
AU  - Huang Q
AD  - Department of Pathology, Ningbo University School of Medicine, Ningbo, Zhejiang 
      315211, P.R. China.
FAU - Deng, Qiuhua
AU  - Deng Q
AD  - Department of Thoracic Surgery, The First Affiliated Hospital, Guangzhou Medical 
      University, Guangzhou, Guangdong 510120, P.R. China.
FAU - Jiang, Lei
AU  - Jiang L
AD  - Department of Pathology, Ningbo University School of Medicine, Ningbo, Zhejiang 
      315211, P.R. China.
FAU - Fang, Rong
AU  - Fang R
AD  - Department of Pathology, Ningbo University School of Medicine, Ningbo, Zhejiang 
      315211, P.R. China.
FAU - Qiu, Yinghua
AU  - Qiu Y
AD  - Unigene Bioscience Co., Ltd., Ningbo, Zhejiang 315211, P.R. China.
FAU - Wang, Ping
AU  - Wang P
AD  - Department of Pathology, Ningbo University School of Medicine, Ningbo, Zhejiang 
      315211, P.R. China.
FAU - Zhou, Jeff X
AU  - Zhou JX
AD  - Department of Pathology, Ningbo University School of Medicine, Ningbo, Zhejiang 
      315211, P.R. China.
FAU - Yang, Haihong
AU  - Yang H
AD  - Department of Thoracic Surgery, The First Affiliated Hospital, Guangzhou Medical 
      University, Guangzhou, Guangdong 510120, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20160127
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC4774594
OTO - NOTNLM
OT  - anaplastic lymphoma kinase
OT  - crizotinib
OT  - lung cancer
OT  - targeted therapy
EDAT- 2016/03/22 06:00
MHDA- 2016/03/22 06:01
PMCR- 2016/01/27
CRDT- 2016/03/22 06:00
PHST- 2014/11/25 00:00 [received]
PHST- 2015/11/11 00:00 [accepted]
PHST- 2016/03/22 06:00 [entrez]
PHST- 2016/03/22 06:00 [pubmed]
PHST- 2016/03/22 06:01 [medline]
PHST- 2016/01/27 00:00 [pmc-release]
AID - OL-0-0-4157 [pii]
AID - 10.3892/ol.2016.4157 [doi]
PST - ppublish
SO  - Oncol Lett. 2016 Mar;11(3):1651-1656. doi: 10.3892/ol.2016.4157. Epub 2016 Jan 
      27.